BIMINI Biotech is a preclinical stage company developing novel first-in-class small molecule therapeutics in oncology with a focus on lymphomas and leukemia, malignancies with a strong unmet need. BIMINI’s approach is based on pioneering research by Institute of Oncology Research (CH) that targets Wiskott Aldrich Syndrome protein (or WASp), an actin nucleation related protein expressed exclusively in hematopoietic cells. The actin cytoskeleton is a network of fibers and tubes that gives the cell firmness, shape and mobility and is important for cell division. Depending on the type of tumor, activation or inhibition of the protein can elicit a strong anti-cancer effect. BIMINI has a portfolio of two proprietary agents that can inhibit or activate WASp. Our approach has shown promising in vitro and in vivo results.